药品管理新规5月施行，修改条款超90%

Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" introduces significant changes aimed at enhancing drug safety and innovation, with a focus on accelerating drug approval processes and establishing market exclusivity for pediatric and rare disease drugs [1][4][8]. Group 1: Regulatory Changes - The revised regulations represent the first comprehensive update in 23 years, with over 90% of the provisions modified, reflecting a shift towards stricter compliance and enforcement [1][2]. - The regulations elevate previously established policies on drug review and approval to legal requirements, indicating a higher level of compliance obligation for pharmaceutical companies [2]. Group 2: Innovation and R&D - The regulations explicitly support research and development (R&D) innovation, emphasizing clinical value as a core principle for drug development and encouraging the creation of new drugs [4][6]. - The introduction of four accelerated drug approval pathways aims to expedite the market entry of innovative drugs, with a notable reduction in average review times by 25% since 2018 [7][8]. Group 3: Market Dynamics - The regulatory changes are expected to drive a transformation in the pharmaceutical industry, pushing companies towards original innovation and global market competition, moving away from low-level fast-follow strategies [1][6]. - The introduction of market exclusivity periods for pediatric drugs (up to 2 years) and rare disease drugs (up to 7 years) is anticipated to enhance the attractiveness of these segments for pharmaceutical companies [8]. Group 4: Compliance and Responsibility - The regulations shift the focus from managing drug production companies to managing drug marketing authorization holders, thereby enforcing stricter accountability throughout the drug lifecycle [10][11]. - The new compliance framework necessitates that companies establish comprehensive quality assurance systems and adhere to stringent regulatory standards, which may increase operational costs, particularly for smaller firms [16][17]. Group 5: Quality Control and Enforcement - The regulations enhance quality supervision, particularly in online sales, and clarify the responsibilities of drug marketing authorization holders and third-party platforms [15][16]. - Stricter penalties for violations are introduced, including increased fines and enhanced criminal accountability, which are expected to raise compliance costs and pressure smaller companies [16][17].